Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Yogurt Probiotics Used to Fight Cancer

By BiotechDaily International staff writers
Posted on 04 Apr 2013
Probiotics, similar to those found in yogurt, which are found to enhance digestive health, are now being considered as a possible weapon to be used in the war against cancer.

This is the focus of investigators from the Cancer Institute of New Jersey (New Brunswick, USA), a Center of Excellence of the University of Medicine and Dentistry of New Jersey (UMDNJ)-Robert Wood Johnson Medical School, who are studying the effectiveness of probiotics as they relate to the outcomes of bone marrow transplant for blood cancer patients.

Some patients with lymphoma, leukemia, and myeloma are treated with an allogeneic bone marrow transplant where the donor is a blood relative or is unrelated but has the same tissue type. Donated cells can generate an immune attack against cancer cells in the patient, but they can also attack normal healthy cells and tissues. This attack, known as graft-versus-host disease (GVHD), is one of the key problems of transplantation and occurs in the gastrointestinal (GI) tract in 25%–40% of patients who undergo the allogeneic procedure.

When the GI tract breaks down, bacteria in the colon can invade the body and cause nasty infections that trigger the immune system. GVHD can then advance to the liver and other organs. Probiotics are known to decrease the growth of specific types of bacteria. Investigators from the Cancer Institute of New Jersey, who have already determined the probiotic Lactobacillus GG is safe in relation to GVHD, are now exploring its effectiveness as part of the PERFECT (Probiotic Enteric Regimen For Easing Complications of Transplant) trial. The research is being led by Roger Strair, MD, PhD, chief of hematologic alignancies/hematopoietic stem cell transplantation at the Cancer Institute of New Jersey.

“By further exploring the effects of probiotics on graft-versus-host-disease, we may be able to identify methods of preventing infection. We are grateful for their support,” noted Dr. Strair, professor of medicine at UMDNJ-Robert Wood Johnson Medical School.

Related Links:
Cancer Institute of New Jersey



Channels

Genomics/Proteomics

view channel
Image: Bacteriophage EFDG1 visualized by transmission electron microscopy (TEM) at a magnification of 20,000–30,000 times. Note that some phages are still bound to remains of the dead bacteria (Photo courtesy of the Hebrew University of Jerusalem).

Bacteriophage Therapy Eliminates Multidrug Resistant Bacterial Infections

Bacteriophage therapy has been shown to be an effective approach for treating infections caused by drug-resistant strains of the bacterium Enterococcus faecalis. E. faecalis, a bacterium inhabiting... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.